Summary This study sought to produce monoclonal antibodies (MAbs) which reacted with the MUC2 core protein. Two MAbs [3A2 (IgGl) and 4F1 (IgM)] were produced by immunising female BALB/c mice with gel-formed mucin from the LS174T colon cancer cell line followed by a KLH conjugate of a 29 amino acid synthetic peptide whose sequence was derived from the variable number of tandem repeats (VNTR) region of a MUC2 cDNA clone.
Summary This study sought to produce monoclonal antibodies (MAbs) which reacted with the MUC2 core protein. Two MAbs [3A2 (IgGl) and 4F1 (IgM)] were produced by immunising female BALB/c mice with gel-formed mucin from the LS174T colon cancer cell line followed by a KLH conjugate of a 29 amino acid synthetic peptide whose sequence was derived from the variable number of tandem repeats (VNTR) region of a MUC2 cDNA clone.
The MAbs reacted with synthetic MUC2 VNTR peptides but not synthetic MUCI or MUC3 VNTR peptides, and showed specific reactivity in Western blotting with a high molecular weight protein produced by the LS174T colon carcinoma cell line. The use of shorter peptides indicated that the minimum peptide epitopes for these MAbs were different. Mab 3A2 reacted with amino acids 5-19 of the MUC2 VNTR by inhibition ELISA but not by direct ELISA, while 4FI reacted with this peptide in both assays. Furthermore, 4FI reacted in direct ELISA when a larger (29 amino acid) MUC2-derived peptide was coated onto the assay plate by incubating in carbonate buffer or by drying the peptide onto the assay plate, while 3A2 only reacted when this peptide was coated in carbonate buffer. The different specificity of the MAbs was also illustrated by the reactivity of 4F1 but not 3A2 with partially deglycosylated cystic fibrosis mucin.
Immunohistochemical analysis with these MAbs revealed a strong reactivity with lung, gastric and colon tumours relative to normal tissue, with some breast and ovarian tumours also reacting. Both MAbs stained some normal goblet cells in the perinuclear region but not the mucin droplet or secreted mucin, indicating a reaction with immature (poorly glycosylated) mucin in the endoplasmic reticulum and/or golgi, but not with mature (fully glycosylated) mucin. In contrast, tumours showed strong diffuse cytoplasmic staining. 4F1 also showed weak apical cytoplasmic staining in some goblet cells and stained some tumours which showed no reactivity with 3A2.
These antibodies should prove useful in the study of MUC2 structure and function, and in the diagnosis of some tumours.
Mucins are a family of highly glycosylated, high molecular weight (>200 kDa) glycoproteins present on the surface of many epithelial cells . Increased expression of mucin epitopes on tumour cells makes them suitable candidates as tumour markers. Five distinct gene loci have now been identified in humans, these being renamed MUC1, MUC2 and MUC3 (Human Gene Mapping Nomenclature Committee, 1989 ) and the names MUC4 and MUC5 have been proposed Aubert et al., 1991 (Gendler et al., 1987; Gum et al., 1989; Porchet et al., 1991; Aubert et al., 1991) . Many monoclonal antibodies (MAbs) reacting with the MUC1 VNTR have been reported (Gendler et al., 1988; Xing et al., 1990; Layton et al., 1990; Price et al., 1990) , and assays incorporating some of these MAbs have been shown to be particularly useful in monitoring patients with breast and ovarian cancer (Ward et al., 1993; Safi et al., 1991; Bhargava et al., 1989) . As well as overexpression of MUC1, altered glycosylation of the VNTR is responsible for the exposure of these peptide epitopes in tumours (Gendler et al., 1988; Devine et al., 1990a) . *Despite the success of MUC1 VNTR-reactive MAbs, only a few MAbs reacting with other VNTR have been reported Price et al., 1991) , and the use of these MAbs for diagnosis and therapy has not been investigated. The MUC2 mucin is of particular interest since this is a major component of mucus produced by patients with colon and lung cancer, as well as those with cystic fibrosis (Gum et al., 1989; Gerard et al., 1990; Jany et al., 1991) . Subsequently, by immunising with native colon cancer mucin and a KLH-synthetic peptide conjugate containing the 23 amino acid MUC2 VNTR sequence, we have produced anti-MUC2 VNTR MAbs which react with the intact mucin. These MAbs show a high reactivity with colon, gastric, and lung tumours by immunohistochemistry, and may prove useful in the diagnosis and therapy of these tumours.
Materials and methods

Peptides
The peptides used in this study are shown in Table I . The Ml, M2 and T4N1 peptides were synthesised using an Applied Biosystems Model 430A automated peptide synthesiser (Forster City, CA, USA) by Merrifield solid phase synthesis (Hodges & Merrifield, 1975) . Ml corresponds to the 20 amino acid MUC1 repeat plus the first four amino acids of the next repeat (Gendler et al., 1987) ; M2 corresponds to the first 23 amino acid MUC2 repeat plus the first four amino acids of the next repeat (Gum et al., 1989) , with KY added to the N-terminal for conjugation; T4N1 corresponds to the N-terminus of mouse CD4 (Clark et al., 1988) , and was used as a control. The M25 19 peptide, synthesised on 'pins' (Geysen et al., 1984) , was donated by Chiron Mimotopes, Australia, and corresponded to amino acids 5-19 of the first MUC2 repeat (Gum et al., 1989) . The M2N and M2c peptides were produced by cyanogen bromide cleavage of the M2 peptide (Gross, 1967) , and correspond to the N-terminal and C-terminal portions of the M2 peptide. The M3 peptide was prepared using the 'tea bag' method (Houghton, 1985) , and represents the 17 amino acid MUC3 repeat plus the first five amino acids of the next repeat (Gum et al., 1990) , with lysine attached to the N-terminus for conjugation. The pep- (Zegers et al., 1990 ).
Mucins
The LS1 74T and HT29-SB colon cancer cell lines have been shown to secrete significant quantities of mucin (Devine et al., 1991 (Layton et al., 1990) . Positive clones were then checked by ELISA on Ml, and by immunoblotting on LS174T and HT29-SB mucins . Those showing specificity for LS174T and M2 were cloned by limiting dilution. The subclass of MAbs was determined by dual-determinant ELISA using subclass-specific antibodies to capture MAbs and anti-mouse Ig-peroxidase (Silenus, Australia) to detect bound MAb.
ELISA
All assays were performed in duplicate, with the percentage coefficient of variation of duplicates being < 10% in all cases. Mabs BC2 (IgGI), BC3 (IgM), 401/21 (IgGI), and FMI (IgM) were used as control antibodies (Xing et al., 1989; Skerritt & Hill, 1990; Devine et al., 1990b) . BC2 and BC3 react with the minimum epitope APDTR on the MUCI VNTR , 401/21 reacts with wheat protein gliadins (Skerritt & Hill, 1990) , while the specificity of FM1 has not been determined.
Solid-Phase ELISA Peptides (2.5 jig dry weight ml-') or mucins (40 tLg dry weight LS174T mucin ml-' or 5 jg dry weight CF mucin ml-') were coated onto a Falcon flexible assay plate (Becton Dickinson, USA) by incubating overnight at 4'C in 0.1 M carbonate buffer pH 9.6, or by drying onto the plate in vacuo at 30°C. Plates were blocked for 2 h at room temperature (RT) with Blocking Reagent (BoehringerMannheim, IN, USA, cat. no. 1142372), and incubated overnight with MAb in phosphate buffered saline containing 0.05% Tween-20 (PBS-Tween). Bound MAb was detected using anti-mouse Ig-peroxidase (Silenus, Australia) and ABTS substrate (Devine et al., 1990b) . Plates were washed three times with PBS-Tween between each incubation, and checkerboard titrations of antigen and MAb were performed. Blocked plates containing no antigen were also tested to determine any non-specific binding.
Inhibition ELISA Optimal concentrations of antigens and MAbs were determined by checkerboard ELISA, and inhibition ELISA was performed (Layton et al., 1990) . Briefly, MAbs at twice the required concentration (3A2 ascites 2000-', 4F1 ascites 5000-1) were incubated for 3 h at RT with an equal volume of peptide (64 fM) in PBS-Tween. 'No inhibition' (MAb plus PBS-Tween) and 'total inhibition' (PBS-Tween, no MAb) incubations were also performed. Subsequently, 50 ,il was transferred to a peptide-coated plate (1.25 gLg dry weight ml-' for 3A2, 0.125 ytg dry weight ml' for 4F1) and the assay was completed as above. Inhibition was calculated as described (Layton et al., 1987) .
Cell staining
The reactivity of MAbs was tested on a panel of colon carcinoma cell lines (LS174T, LIM1899, LIM2099, LIM2358, LIM2405, LIM2412, LIM2463, LIM2537) (Whitehead et al., 1985 . Adherent cell lines were grown to confluence, scraped and a pellet of cells was embedded in OCT freezing mixture (Miles Laboratories, USA) and stored at -20'C until cut. Cells grown in suspension were harvested, pelleted and processed similarly. The sections were fixed at room temperature in cold acetone for 10 min and air dried before staining with MAbs using the standard two-layer immunoperoxidase technique. Mabs (hybridoma supernatant at 10-') were detected using rabbit anti-mouse peroxidase (DAKO, USA) followed by incubation with DAB substrate.
Western blotting Proteins were separated on 3-15% SDS-polyacrylamide gels, and Western blotting was performed as described, with prestained high molecular weight markers (BioRad, MA, USA) run alongside the samples (Devine et al., 1990a) . Gel-formed mucin was dissolved in Tris buffer pH 6.8 containing 3% SDS and 20% glycerol. In some cases, 5% 2-mercaptoethanol was also included to reduce disulphide linkages. The samples were boiled for 10 min before performing electrophoresis. Non-malignant colonic, gastric, lung and breast tissue, obtained from non-involved resection margins were also assessed and expression of the antigens described. Mesothelioma cells were isolated from pleural fluid and treated as above, except fixation was done in methacarn.
Immunohistochemistry specimens and analysis
Immunohistochemistry techniques Immunohistochemistry was performed (McGuckin et al., 1990) with MAb ascites at 1000-1. Sections were stained with 3A2, 4F1, and negative control MAb FM1.
peptide was inhibited by M2, M25 ,9, M2N, and M2C peptides, but not the M3 or T4N1 peptides (Ml not tested).
However, the M2, M25-,9 and M2C peptides showed greater inhibition of MAb binding than the M2N peptide, particularly with 3A2. It is also of interest to note that MAb 4F1 also reacted with the M25 19 peptide by solid-phase ELISA while MAb 3A2 showed no reactivity with this peptide in this assay system. Furthermore, when peptides were dried in vacuo on to the microtitre plate, 3A2 showed no reactivity with M2 while 4F1 reacted strongly (not shown).
Reactivity of antibodies with cystic fibrosis (CF) mucin The reactivity of MAbs with native and partially deglycosylated cystic fibrosis mucin was determined by solid-phase ELISA. Mab 3A2 showed very weak reactivity with either mucin (not shown), while 4F1 reacted weakly with native mucin and showed strong reactivity with partially deglycosylated CF mucin produced by TFMSA treatment ( Figure  2 were negative in all cases, while MAbs BC2 and BC3 reacted with HMFGM and the Ml peptide but not with other antigens (not shown). After these hybridomas were cloned and produced as ascites in mice, checkerboard titration showed that the reactivity of both MAbs with M2 peptide and LS174T mucin was concentration dependent (Figure 1 ). The results of inhibition ELISA with different peptides is shown in Table I Figure 2 Reactivity of MAb 4F1 with native (0) and partially deglycosylated (A) cystic fibrosis mucin by direct ELISA. Mucin was coated at 5 Lg dry weight ml-' by incubation in vacuo at 30C as described in the Materials and methods. Mab 3A2 showed weak reactivity with both mucins, while 401/21 and FMI were negative (not shown). (Figure 3 ). Both MAbs reacted under reducing and non-reducing conditions with a single high molecular weight band of molecular weight greater than 400 kDa. There was no reaction, however, with gel-formed mucin produced by the HT29-SB colon carcinoma cell line (not shown).
Ascites dilution
Reactivity of antibodies with non-malignant tissue by immunoperoxidase staining Both 4F1 and 3A2 antibodies reacted with some epithelial components of non-malignant colonic, gastric and lung tissue, but not with non-malignant breast epithelium. In normal colon, 4F1 antigen expression was typified by diffuse cytoplasmic staining of the colonic mucosal surface, although antigen was not detected within goblet cell mucin droplets. The proportion of positive cells varied between specimens from 10 to 75% of surface epithelial cells, and staining decreased deeper in the mucosal crypts. Occasionally, stronger granular staining in peri-and supra-nuclear regions of goblet cells was observed (Figure 4a ). In contrast, 3A2 expression was mainly restricted to such granular staining in the basal region of goblet cells, although some specimens showed a small proportion of cells with diffuse cytoplasmic staining similar to that found for 4F1. In most specimens, less than 10% of goblet cells were positive with most staining in the outer cells of crypts (Figure 4b,c) The antibodies also reacted with 5/6 (4F1) and 3/6 (3A2) mesotheliomas.
Discussion
The isolation of cDNA clones coding for the protein core of MUC2 mucin (Gum et al., 1990) , and firm conclusions regarding the epitopes for these MAbs cannot be drawn from these experiments. Further experiments with shorter overlapping peptides are needed to define the minimum epitopes of these MAbs. Differences in the fine specificity of MAbs 3A2 and 4F1 were also illustrated by the reactivity of 3A2 with the M25-19 peptide by inhibition ELISA but not direct ELISA, while 4F1 reacted with this peptide in both assay systems. In addition, the reactivity of 3A2 with the M2 peptide in direct ELISA was dependent on the method of plate coating. This may explain the weaker reactivity of 3A2 with LS174T mucin and CF mucin by direct ELISA. In addition, the consensus sequence of the MUC2 VNTR from intestine is slightly different to that of tracheobronchial tissue (Gerard et al., 1991) , so the difference in reactivity with CF mucin may be due to differences in the minimum epitopes of 3A2 and 4F1.
The observations from immunohistochemical staining of both normal and malignant tissues are consistent with 4F1 and 3A2 recognising different epitopes on the protein core of the MUC2 mucin. Cellular distribution of these epitopes in normal gastro-intestinal and respiratory tissues was similar to that described for antigens recognised by polyclonal antibodies prepared against deglycosylated LS174T mucin (Yan et al., 1990) and deglycosylated sputum from a cystic fibrosis patient (Perini et al., 1989) . The perinuclear granular staining, seen particularly with 3A2, probably represents detection of the protein core in the endoplasmic reticulum or golgi apparatus prior to the completion of glycosylation. The lack of reactivity of both antibodies with mucin droplets of globlet cells and luminal secretions suggests low reactivity with the mature mucin in normal cells. The observation that not all cells of a given type showed equal expression of either epitope is consistent with the findings of other studies utilising various antibodies to colonic and/or respiratory mucins (Yan et al., 1990; Perini et al., 1989; Podolsky et al., 1986; Finkbeiner & Basbaum, 1988) . These findings suggest either phenotypic or stage dependent maturational differences may exist in mucin production patterns of morphologically similar cells.
Detection of the 4F1 and 3A2 epitopes in colonic, gastric, lung, breast, and ovarian cancers demonstrates continued MUC2 production by at least some carcinomas derived from these organs. The expression of both epitopes in some malignancies was much greater than their expression by corresponding non-malignant cells. Increased expression in cancers could reflect either increased production and/or underglycosylation of MUC2. The loss of compartmentalisation of granular cytoplasmic staining is consistent with the loss of polarity that occurs following malignant transformation of epithelial cells. Larger numbers of specimens are required to fully assess the relative expression in different histological types. However, it appears the degree of differentiation has little effect on expression in colon and gastric carcinomas. MUC2 was expressed in both mucinous and non-mucinous ovarian carcinomas. Unfortunately, this finding prevents the use of MUC2 detection for differential diagnosis of gastrointestinal and mucinous ovarian pelvic and peritoneal malignancies. In addition, MUC2 was also expressed by mesotheliomas, and these MAbs could not be used for the differential diagnosis of mesothelioma and adenocarcinoma. The 4F1 and 3A2 epitope expression detected in some cases of breast carcinoma is consistent with the findings of Yan et al. (1990) who found a small percentage of cells positive for antibodies against deglycosylated colon mucin in one of five breast cancers, and Jany et al. (1991) who demonstrated the presence of MUC2 RNA in mammary tissue. Although antigen was not detected in normal breast duct epithelium, further analysis is required as MUC2 may be expressed by foetal or lactating breast epithelium.
These antibodies should prove useful in the study of MUC2 structure and function, and also have potential as diagnostic and therapeutic agents. The production of second generation anti-peptide antibodies represents a useful method of producing anti-tumour reagents, and this technology may also be applied to the production of MAbs to the other mucin core proteins.
